ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors
The expected combined toxicity is often low for anti-HER2 monoclonal antibodies. For most scenarios with CDK4/6, PARP, or mTOR inhibitors, exercising caution is recommended.
Authors
- Carmen Criscitiello (ORCID: https://orcid.org/0000-0001-9064-0113)
- Diogo Martins-Branco (ORCID: https://orcid.org/0000-0002-7214-4818)
- Bharti Devnani (ORCID: https://orcid.org/0000-0001-8465-0905)
- Evert S.M. van Aken (ORCID: https://orcid.org/0000-0003-2358-4435)
- Corrie A.M. Marijnen (ORCID: https://orcid.org/0000-0003-0189-5953)
- Antonin Lévy (ORCID: https://orcid.org/0000-0003-4798-8899)
- George E. Pentheroudakis (ORCID: https://orcid.org/0000-0002-6632-2462)
- Séan M. O’Cathail (ORCID: https://orcid.org/0000-0001-5574-9199)
- Monique C. de Jong (ORCID: https://orcid.org/0000-0001-7736-6789)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Emmanouil Fokas (ORCID: https://orcid.org/0000-0003-1601-6165)
- Gábor Liposits (ORCID: https://orcid.org/0000-0002-8204-3949)
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- Claus Belka (ORCID: https://orcid.org/0000-0002-1287-7825)
- P Boot
- Ilaria Colombo (ORCID: https://orcid.org/0000-0002-0602-8667)
- Ajeet Kumar Gandhi (ORCID: https://orcid.org/0000-0001-5713-0963)
- Marcel Verheij (ORCID: https://orcid.org/0000-0002-8079-7421)
- Florian Lordick (ORCID: https://orcid.org/0000-0001-8591-9339)
- Dirk De Ruysscher (ORCID: https://orcid.org/0000-0001-9269-6567)
- Anne Hansen Ree (ORCID: https://orcid.org/0000-0002-8264-3223)
- Umberto Ricardi (ORCID: https://orcid.org/0000-0003-4406-7621)
- Jorge Barriuso (ORCID: https://orcid.org/0000-0002-5641-9105)
- Maximilian Niyazi (ORCID: https://orcid.org/0000-0002-7711-9486)
- Gerben Borst
- Arsela Prelaj (ORCID: https://orcid.org/0000-0002-3863-088X)
- Stephanie Kroeze (ORCID: https://orcid.org/0000-0002-1342-5310)
- Evandro de Azambuja (ORCID: https://orcid.org/0000-0001-9501-4509)
- I. L. Ray-Coquard
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Luís Castelo-Branco (ORCID: https://orcid.org/0000-0002-3967-530X)
- Ewa Szutowicz
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Université Libre de Bruxelles (BE)
- Radboud University Nijmegen (NL)
- All India Institute of Medical Sciences Jodhpur (IN)
- Innlandet Hospital Trust (NO)
- Université Paris-Saclay (FR)
- Manchester Academic Health Science Centre (GB)
- European Society for Medical Oncology (CH)
- Akershus University Hospital (NO)
- Institut Jules Bordet (BE)
- Institut Gustave Roussy (FR)
- Cork University Hospital (IE)
- Radboud University Medical Center (NL)
- LMU Klinikum (DE)
- Research Institute Hospital 12 de Octubre (ES)
- Integrated Oncology (United States) (US)
- Ente Ospedaliero Cantonale (CH)
- Hospital Universitario 12 De Octubre (ES)
- Centre Léon Bérard (FR)
- Dana-Farber Cancer Institute (US)
- Breast Center (CH)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- University Children's Hospital Tübingen (DE)
- Dr. Ram Manohar Lohia Institute of Medical Sciences (IN)
- The Christie NHS Foundation Trust (GB)
- Erasmus MC Cancer Institute (NL)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Kantonsspital Aarau (CH)
- University of Turin (IT)
- European Institute of Oncology (IT)
- Gdańsk Medical University (PL)
- University of Glasgow (GB)
- Ludwig-Maximilians-Universität München (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.radonc.2025.111330
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- European Society for Medical Oncology